Cell and Gene Outsourcing

  1. Manufacturing Life-Saving Gene Therapies 2/24/2021

    Take a look behind the scenes and hear firsthand about the commitment to patients and clients at Andelyn Biosciences.

  2. Viral Vector Manufacturing: Improve Efficiency With A Platform Approach 9/25/2023

    Learn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.

  3. Mitigating Risk Through Product Characterization 7/17/2019

    In this webinar, multiple approaches to characterizing the physico-chemical and structural attributes of therapeutic mAbs is presented with a focus on how it influences the resulting biological activity.

  4. Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats

    Explore an integrated drug substance/drug product CMC strategy and technical case studies that provide insight into delivering product-specific solutions and enabling the acceleration of novel molecular formats.

  5. GLP And The Impact To Start Up Companies 4/18/2022

    Good Laboratory Practice is often used in laboratories and is necessary for specific investigations. What does it mean? And how can it help start-up companies? Watch this video to learn more.

  6. Pioneering Solutions That Turn Hope Into Reality

    The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.

  7. A Robust And Scalable Suspension Platform For AAV Manufacturing

    Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.

  8. Cell & Gene Therapy Development: Characterization Of Cellular Starting Material 6/21/2024

    Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

  9. Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity

    Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.

  10. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma.